This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Bristol-Myers Squibb Compnay, Five Prime Therapeutics, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3,745 
1 out of 77 
Years Active: 2022
Title: Ke Xu: Innovator in Cancer Therapy
Introduction
Ke Xu is a notable inventor based in Plainsboro, NJ (US). He has made significant contributions to the field of cancer therapy, particularly in the treatment of pancreatic cancer. His innovative approach combines specific antibodies to enhance treatment efficacy.
Latest Patents
Ke Xu holds a patent for a groundbreaking invention titled "Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer." This patent outlines methods for treating pancreatic cancer using particular dosage regimes of antibodies that bind to the colony stimulating factor 1 receptor (CSF1R), such as cabiralizumab, in combination with antibodies that bind to programmed cell death 1 (PD-1), like nivolumab. He has 1 patent to his name.
Career Highlights
Throughout his career, Ke Xu has worked with prominent companies in the pharmaceutical industry. He has been associated with Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company, where he has contributed to the development of innovative therapies.
Collaborations
Ke Xu has collaborated with esteemed colleagues in his field, including Katherine E. Lewis and Serena Kimi Perna. Their combined expertise has furthered advancements in cancer treatment.
Conclusion
Ke Xu's work in developing combination therapies for pancreatic cancer showcases his commitment to innovation in the medical field. His contributions are paving the way for more effective cancer treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile